Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis
Summary Background Lamivudine and entecavir reduce hepatic events and death in chronic hepatitis B (CHB) patients with cirrhosis, but the impact of tenofovir disoproxil fumarate (TDF) is less well studied. Aim To investigate the effectiveness of TDF therapy in CHB patients with cirrhosis. Methods We...
Gespeichert in:
| Veröffentlicht in: | Alimentary pharmacology & therapeutics 2019-11, Vol.50 (9), p.1037-1048 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1048 |
|---|---|
| container_issue | 9 |
| container_start_page | 1037 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 50 |
| creator | Liu, Ken Choi, Jonggi Le, An Yip, Terry Cheuk‐Fung Wong, Vincent Wai‐Sun Chan, Stephen Lam Chan, Henry Lik‐Yuen Nguyen, Mindie H. Lim, Young‐Suk Wong, Grace Lai‐Hung |
| description | Summary
Background
Lamivudine and entecavir reduce hepatic events and death in chronic hepatitis B (CHB) patients with cirrhosis, but the impact of tenofovir disoproxil fumarate (TDF) is less well studied.
Aim
To investigate the effectiveness of TDF therapy in CHB patients with cirrhosis.
Methods
We studied TDF‐treated and untreated CHB patients with cirrhosis from three tertiary centres. TDF cohort included consecutive patients who received TDF for ≥12 months while the untreated cohort were historical controls receiving routine clinical care prior to the availability of anti‐viral therapy. The primary outcome was 5‐year cumulative probability of hepatocellular carcinoma (HCC) with secondary outcomes being hepatic decompensation and death or liver transplantation (LT).
Results
A total of 1088 (291 untreated and 797 TDF‐treated) patients were included in the study. Five‐year cumulative probabilities in untreated vs TDF‐treated cohorts were 14.9% vs 9.8% for HCC (P = .07), 22.3% vs 5.9% for decompensation (P |
| doi_str_mv | 10.1111/apt.15499 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2290967683</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2306387943</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3539-7e5498c228c333490845f7ab65cc2b0398ad45c5b589b9c7fccb885394d8879d3</originalsourceid><addsrcrecordid>eNp1kVFP3SAYhsky4zkevdgfWEh2o8mqFEoLl864zcREL47XhH6lOZgWOmin_gL_ttS6XZjIDYQ83xNeXoS-5OQ0T-tMD-NpzgspP6F1zkqeUcLKz2hNaCkzKnK2Qgcx3hNCyorQfbRiOacFI8UaPW-N863_awNubPRD8I-2w-3U66BHg4NpJjAR78ygRw-m66ZOBww6gHW-199xY8D3g3FRj9Y7rF2TrvS4w9Zh2AXvLCzTdrQR_8Dzybgx4gebILAh7Hy08RDttbqL5uht36C7n5fbi9_Z9c2vq4vz6wwYZzKrTIopgFIBjLFCElHwttJ1yQFoTZgUuik48JoLWUuoWoBaiDRZNEJUsmEbdLx4U9I_k4mj6m2cc2ln_BQVpZLIsioFS-i3d-i9n4JLr1OUkZIlXzFTJwsFwccYTKuGYNPvPamcqLkdldpRr-0k9uubcap70_wn_9WRgLMFeLCdefrYpM5vt4vyBbkGm0U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2306387943</pqid></control><display><type>article</type><title>Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis</title><source>MEDLINE</source><source>Wiley Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><creator>Liu, Ken ; Choi, Jonggi ; Le, An ; Yip, Terry Cheuk‐Fung ; Wong, Vincent Wai‐Sun ; Chan, Stephen Lam ; Chan, Henry Lik‐Yuen ; Nguyen, Mindie H. ; Lim, Young‐Suk ; Wong, Grace Lai‐Hung</creator><creatorcontrib>Liu, Ken ; Choi, Jonggi ; Le, An ; Yip, Terry Cheuk‐Fung ; Wong, Vincent Wai‐Sun ; Chan, Stephen Lam ; Chan, Henry Lik‐Yuen ; Nguyen, Mindie H. ; Lim, Young‐Suk ; Wong, Grace Lai‐Hung</creatorcontrib><description>Summary
Background
Lamivudine and entecavir reduce hepatic events and death in chronic hepatitis B (CHB) patients with cirrhosis, but the impact of tenofovir disoproxil fumarate (TDF) is less well studied.
Aim
To investigate the effectiveness of TDF therapy in CHB patients with cirrhosis.
Methods
We studied TDF‐treated and untreated CHB patients with cirrhosis from three tertiary centres. TDF cohort included consecutive patients who received TDF for ≥12 months while the untreated cohort were historical controls receiving routine clinical care prior to the availability of anti‐viral therapy. The primary outcome was 5‐year cumulative probability of hepatocellular carcinoma (HCC) with secondary outcomes being hepatic decompensation and death or liver transplantation (LT).
Results
A total of 1088 (291 untreated and 797 TDF‐treated) patients were included in the study. Five‐year cumulative probabilities in untreated vs TDF‐treated cohorts were 14.9% vs 9.8% for HCC (P = .07), 22.3% vs 5.9% for decompensation (P < .01) and 13.1% vs 1.1% for death or LT (P < .01) respectively. On multivariable Cox regression, TDF treatment was independently associated with reduced risks of HCC (adjusted hazard ratio [aHR] 0.46, P < .01), decompensating events (aHR 0.28, P = .01) and death or LT (aHR 0.06, P < .01). On sensitivity analyses, these risk reductions with TDF treatment were consistently demonstrated regardless of severity of liver disease and prior anti‐viral treatment. TDF treatment led to sustained improvements in most validated prognostic scores for predicting HCC, decompensation and death.
Conclusions
Compared to untreated patients, TDF treatment reduces the risks of HCC, hepatic decompensation and death in CHB patients with cirrhosis at 5 years.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/apt.15499</identifier><identifier>PMID: 31524304</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Adult ; Antiviral Agents - therapeutic use ; Carcinoma, Hepatocellular - mortality ; Carcinoma, Hepatocellular - pathology ; Carcinoma, Hepatocellular - prevention & control ; Cirrhosis ; Cohort Studies ; Death ; Female ; Hepatitis ; Hepatitis B ; Hepatitis B, Chronic - complications ; Hepatitis B, Chronic - drug therapy ; Hepatitis B, Chronic - mortality ; Hepatitis B, Chronic - pathology ; Hepatocellular carcinoma ; Humans ; Lamivudine ; Liver ; Liver cancer ; Liver cirrhosis ; Liver Cirrhosis - complications ; Liver Cirrhosis - drug therapy ; Liver Cirrhosis - mortality ; Liver diseases ; Liver Failure - etiology ; Liver Failure - mortality ; Liver Failure - pathology ; Liver Failure - prevention & control ; Liver Neoplasms - mortality ; Liver Neoplasms - pathology ; Liver Neoplasms - prevention & control ; Liver transplantation ; Liver Transplantation - statistics & numerical data ; Male ; Medical treatment ; Middle Aged ; Patients ; Retrospective Studies ; Survival Analysis ; Tenofovir ; Tenofovir - therapeutic use ; Transplantation ; Treatment Outcome</subject><ispartof>Alimentary pharmacology & therapeutics, 2019-11, Vol.50 (9), p.1037-1048</ispartof><rights>2019 John Wiley & Sons Ltd</rights><rights>2019 John Wiley & Sons Ltd.</rights><rights>Copyright © 2019 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3539-7e5498c228c333490845f7ab65cc2b0398ad45c5b589b9c7fccb885394d8879d3</citedby><cites>FETCH-LOGICAL-c3539-7e5498c228c333490845f7ab65cc2b0398ad45c5b589b9c7fccb885394d8879d3</cites><orcidid>0000-0002-0453-3168 ; 0000-0003-2215-9410 ; 0000-0002-7790-1611 ; 0000-0002-2863-9389 ; 0000-0002-6275-4989 ; 0000-0002-1544-577X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fapt.15499$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fapt.15499$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31524304$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Ken</creatorcontrib><creatorcontrib>Choi, Jonggi</creatorcontrib><creatorcontrib>Le, An</creatorcontrib><creatorcontrib>Yip, Terry Cheuk‐Fung</creatorcontrib><creatorcontrib>Wong, Vincent Wai‐Sun</creatorcontrib><creatorcontrib>Chan, Stephen Lam</creatorcontrib><creatorcontrib>Chan, Henry Lik‐Yuen</creatorcontrib><creatorcontrib>Nguyen, Mindie H.</creatorcontrib><creatorcontrib>Lim, Young‐Suk</creatorcontrib><creatorcontrib>Wong, Grace Lai‐Hung</creatorcontrib><title>Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Summary
Background
Lamivudine and entecavir reduce hepatic events and death in chronic hepatitis B (CHB) patients with cirrhosis, but the impact of tenofovir disoproxil fumarate (TDF) is less well studied.
Aim
To investigate the effectiveness of TDF therapy in CHB patients with cirrhosis.
Methods
We studied TDF‐treated and untreated CHB patients with cirrhosis from three tertiary centres. TDF cohort included consecutive patients who received TDF for ≥12 months while the untreated cohort were historical controls receiving routine clinical care prior to the availability of anti‐viral therapy. The primary outcome was 5‐year cumulative probability of hepatocellular carcinoma (HCC) with secondary outcomes being hepatic decompensation and death or liver transplantation (LT).
Results
A total of 1088 (291 untreated and 797 TDF‐treated) patients were included in the study. Five‐year cumulative probabilities in untreated vs TDF‐treated cohorts were 14.9% vs 9.8% for HCC (P = .07), 22.3% vs 5.9% for decompensation (P < .01) and 13.1% vs 1.1% for death or LT (P < .01) respectively. On multivariable Cox regression, TDF treatment was independently associated with reduced risks of HCC (adjusted hazard ratio [aHR] 0.46, P < .01), decompensating events (aHR 0.28, P = .01) and death or LT (aHR 0.06, P < .01). On sensitivity analyses, these risk reductions with TDF treatment were consistently demonstrated regardless of severity of liver disease and prior anti‐viral treatment. TDF treatment led to sustained improvements in most validated prognostic scores for predicting HCC, decompensation and death.
Conclusions
Compared to untreated patients, TDF treatment reduces the risks of HCC, hepatic decompensation and death in CHB patients with cirrhosis at 5 years.</description><subject>Adult</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Carcinoma, Hepatocellular - mortality</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Carcinoma, Hepatocellular - prevention & control</subject><subject>Cirrhosis</subject><subject>Cohort Studies</subject><subject>Death</subject><subject>Female</subject><subject>Hepatitis</subject><subject>Hepatitis B</subject><subject>Hepatitis B, Chronic - complications</subject><subject>Hepatitis B, Chronic - drug therapy</subject><subject>Hepatitis B, Chronic - mortality</subject><subject>Hepatitis B, Chronic - pathology</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>Lamivudine</subject><subject>Liver</subject><subject>Liver cancer</subject><subject>Liver cirrhosis</subject><subject>Liver Cirrhosis - complications</subject><subject>Liver Cirrhosis - drug therapy</subject><subject>Liver Cirrhosis - mortality</subject><subject>Liver diseases</subject><subject>Liver Failure - etiology</subject><subject>Liver Failure - mortality</subject><subject>Liver Failure - pathology</subject><subject>Liver Failure - prevention & control</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver Neoplasms - pathology</subject><subject>Liver Neoplasms - prevention & control</subject><subject>Liver transplantation</subject><subject>Liver Transplantation - statistics & numerical data</subject><subject>Male</subject><subject>Medical treatment</subject><subject>Middle Aged</subject><subject>Patients</subject><subject>Retrospective Studies</subject><subject>Survival Analysis</subject><subject>Tenofovir</subject><subject>Tenofovir - therapeutic use</subject><subject>Transplantation</subject><subject>Treatment Outcome</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kVFP3SAYhsky4zkevdgfWEh2o8mqFEoLl864zcREL47XhH6lOZgWOmin_gL_ttS6XZjIDYQ83xNeXoS-5OQ0T-tMD-NpzgspP6F1zkqeUcLKz2hNaCkzKnK2Qgcx3hNCyorQfbRiOacFI8UaPW-N863_awNubPRD8I-2w-3U66BHg4NpJjAR78ygRw-m66ZOBww6gHW-199xY8D3g3FRj9Y7rF2TrvS4w9Zh2AXvLCzTdrQR_8Dzybgx4gebILAh7Hy08RDttbqL5uht36C7n5fbi9_Z9c2vq4vz6wwYZzKrTIopgFIBjLFCElHwttJ1yQFoTZgUuik48JoLWUuoWoBaiDRZNEJUsmEbdLx4U9I_k4mj6m2cc2ln_BQVpZLIsioFS-i3d-i9n4JLr1OUkZIlXzFTJwsFwccYTKuGYNPvPamcqLkdldpRr-0k9uubcap70_wn_9WRgLMFeLCdefrYpM5vt4vyBbkGm0U</recordid><startdate>201911</startdate><enddate>201911</enddate><creator>Liu, Ken</creator><creator>Choi, Jonggi</creator><creator>Le, An</creator><creator>Yip, Terry Cheuk‐Fung</creator><creator>Wong, Vincent Wai‐Sun</creator><creator>Chan, Stephen Lam</creator><creator>Chan, Henry Lik‐Yuen</creator><creator>Nguyen, Mindie H.</creator><creator>Lim, Young‐Suk</creator><creator>Wong, Grace Lai‐Hung</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>M7N</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0453-3168</orcidid><orcidid>https://orcid.org/0000-0003-2215-9410</orcidid><orcidid>https://orcid.org/0000-0002-7790-1611</orcidid><orcidid>https://orcid.org/0000-0002-2863-9389</orcidid><orcidid>https://orcid.org/0000-0002-6275-4989</orcidid><orcidid>https://orcid.org/0000-0002-1544-577X</orcidid></search><sort><creationdate>201911</creationdate><title>Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis</title><author>Liu, Ken ; Choi, Jonggi ; Le, An ; Yip, Terry Cheuk‐Fung ; Wong, Vincent Wai‐Sun ; Chan, Stephen Lam ; Chan, Henry Lik‐Yuen ; Nguyen, Mindie H. ; Lim, Young‐Suk ; Wong, Grace Lai‐Hung</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3539-7e5498c228c333490845f7ab65cc2b0398ad45c5b589b9c7fccb885394d8879d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Carcinoma, Hepatocellular - mortality</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Carcinoma, Hepatocellular - prevention & control</topic><topic>Cirrhosis</topic><topic>Cohort Studies</topic><topic>Death</topic><topic>Female</topic><topic>Hepatitis</topic><topic>Hepatitis B</topic><topic>Hepatitis B, Chronic - complications</topic><topic>Hepatitis B, Chronic - drug therapy</topic><topic>Hepatitis B, Chronic - mortality</topic><topic>Hepatitis B, Chronic - pathology</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>Lamivudine</topic><topic>Liver</topic><topic>Liver cancer</topic><topic>Liver cirrhosis</topic><topic>Liver Cirrhosis - complications</topic><topic>Liver Cirrhosis - drug therapy</topic><topic>Liver Cirrhosis - mortality</topic><topic>Liver diseases</topic><topic>Liver Failure - etiology</topic><topic>Liver Failure - mortality</topic><topic>Liver Failure - pathology</topic><topic>Liver Failure - prevention & control</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver Neoplasms - pathology</topic><topic>Liver Neoplasms - prevention & control</topic><topic>Liver transplantation</topic><topic>Liver Transplantation - statistics & numerical data</topic><topic>Male</topic><topic>Medical treatment</topic><topic>Middle Aged</topic><topic>Patients</topic><topic>Retrospective Studies</topic><topic>Survival Analysis</topic><topic>Tenofovir</topic><topic>Tenofovir - therapeutic use</topic><topic>Transplantation</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Ken</creatorcontrib><creatorcontrib>Choi, Jonggi</creatorcontrib><creatorcontrib>Le, An</creatorcontrib><creatorcontrib>Yip, Terry Cheuk‐Fung</creatorcontrib><creatorcontrib>Wong, Vincent Wai‐Sun</creatorcontrib><creatorcontrib>Chan, Stephen Lam</creatorcontrib><creatorcontrib>Chan, Henry Lik‐Yuen</creatorcontrib><creatorcontrib>Nguyen, Mindie H.</creatorcontrib><creatorcontrib>Lim, Young‐Suk</creatorcontrib><creatorcontrib>Wong, Grace Lai‐Hung</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Ken</au><au>Choi, Jonggi</au><au>Le, An</au><au>Yip, Terry Cheuk‐Fung</au><au>Wong, Vincent Wai‐Sun</au><au>Chan, Stephen Lam</au><au>Chan, Henry Lik‐Yuen</au><au>Nguyen, Mindie H.</au><au>Lim, Young‐Suk</au><au>Wong, Grace Lai‐Hung</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2019-11</date><risdate>2019</risdate><volume>50</volume><issue>9</issue><spage>1037</spage><epage>1048</epage><pages>1037-1048</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Summary
Background
Lamivudine and entecavir reduce hepatic events and death in chronic hepatitis B (CHB) patients with cirrhosis, but the impact of tenofovir disoproxil fumarate (TDF) is less well studied.
Aim
To investigate the effectiveness of TDF therapy in CHB patients with cirrhosis.
Methods
We studied TDF‐treated and untreated CHB patients with cirrhosis from three tertiary centres. TDF cohort included consecutive patients who received TDF for ≥12 months while the untreated cohort were historical controls receiving routine clinical care prior to the availability of anti‐viral therapy. The primary outcome was 5‐year cumulative probability of hepatocellular carcinoma (HCC) with secondary outcomes being hepatic decompensation and death or liver transplantation (LT).
Results
A total of 1088 (291 untreated and 797 TDF‐treated) patients were included in the study. Five‐year cumulative probabilities in untreated vs TDF‐treated cohorts were 14.9% vs 9.8% for HCC (P = .07), 22.3% vs 5.9% for decompensation (P < .01) and 13.1% vs 1.1% for death or LT (P < .01) respectively. On multivariable Cox regression, TDF treatment was independently associated with reduced risks of HCC (adjusted hazard ratio [aHR] 0.46, P < .01), decompensating events (aHR 0.28, P = .01) and death or LT (aHR 0.06, P < .01). On sensitivity analyses, these risk reductions with TDF treatment were consistently demonstrated regardless of severity of liver disease and prior anti‐viral treatment. TDF treatment led to sustained improvements in most validated prognostic scores for predicting HCC, decompensation and death.
Conclusions
Compared to untreated patients, TDF treatment reduces the risks of HCC, hepatic decompensation and death in CHB patients with cirrhosis at 5 years.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>31524304</pmid><doi>10.1111/apt.15499</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-0453-3168</orcidid><orcidid>https://orcid.org/0000-0003-2215-9410</orcidid><orcidid>https://orcid.org/0000-0002-7790-1611</orcidid><orcidid>https://orcid.org/0000-0002-2863-9389</orcidid><orcidid>https://orcid.org/0000-0002-6275-4989</orcidid><orcidid>https://orcid.org/0000-0002-1544-577X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 2019-11, Vol.50 (9), p.1037-1048 |
| issn | 0269-2813 1365-2036 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2290967683 |
| source | MEDLINE; Wiley Journals; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection) |
| subjects | Adult Antiviral Agents - therapeutic use Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - prevention & control Cirrhosis Cohort Studies Death Female Hepatitis Hepatitis B Hepatitis B, Chronic - complications Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - mortality Hepatitis B, Chronic - pathology Hepatocellular carcinoma Humans Lamivudine Liver Liver cancer Liver cirrhosis Liver Cirrhosis - complications Liver Cirrhosis - drug therapy Liver Cirrhosis - mortality Liver diseases Liver Failure - etiology Liver Failure - mortality Liver Failure - pathology Liver Failure - prevention & control Liver Neoplasms - mortality Liver Neoplasms - pathology Liver Neoplasms - prevention & control Liver transplantation Liver Transplantation - statistics & numerical data Male Medical treatment Middle Aged Patients Retrospective Studies Survival Analysis Tenofovir Tenofovir - therapeutic use Transplantation Treatment Outcome |
| title | Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T02%3A16%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tenofovir%20disoproxil%20fumarate%20reduces%20hepatocellular%20carcinoma,%20decompensation%20and%20death%20in%20chronic%20hepatitis%20B%20patients%20with%20cirrhosis&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Liu,%20Ken&rft.date=2019-11&rft.volume=50&rft.issue=9&rft.spage=1037&rft.epage=1048&rft.pages=1037-1048&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/apt.15499&rft_dat=%3Cproquest_cross%3E2306387943%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2306387943&rft_id=info:pmid/31524304&rfr_iscdi=true |